DK3792260T3 - Azabenzimidazolforbindelser og lægemiddel - Google Patents

Azabenzimidazolforbindelser og lægemiddel Download PDF

Info

Publication number
DK3792260T3
DK3792260T3 DK19800286.7T DK19800286T DK3792260T3 DK 3792260 T3 DK3792260 T3 DK 3792260T3 DK 19800286 T DK19800286 T DK 19800286T DK 3792260 T3 DK3792260 T3 DK 3792260T3
Authority
DK
Denmark
Prior art keywords
drug
azabenzimidazole compounds
azabenzimidazole
compounds
Prior art date
Application number
DK19800286.7T
Other languages
Danish (da)
English (en)
Inventor
Kouya OIKAWA
Sho Hirai
Kazuhiko Wakita
Akiko FUJIBAYASHI
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of DK3792260T3 publication Critical patent/DK3792260T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK19800286.7T 2018-05-08 2019-05-07 Azabenzimidazolforbindelser og lægemiddel DK3792260T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018089867 2018-05-08
PCT/JP2019/018201 WO2019216294A1 (ja) 2018-05-08 2019-05-07 アザベンゾイミダゾール化合物及び医薬

Publications (1)

Publication Number Publication Date
DK3792260T3 true DK3792260T3 (da) 2024-10-14

Family

ID=68467433

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19800286.7T DK3792260T3 (da) 2018-05-08 2019-05-07 Azabenzimidazolforbindelser og lægemiddel

Country Status (35)

Country Link
US (1) US12319683B2 (https=)
EP (1) EP3792260B1 (https=)
JP (1) JP7235047B2 (https=)
KR (1) KR102819951B1 (https=)
CN (1) CN112368282B (https=)
AU (1) AU2019265134B2 (https=)
BR (1) BR112020022662A2 (https=)
CA (1) CA3099655A1 (https=)
CL (1) CL2020002868A1 (https=)
CO (1) CO2020013848A2 (https=)
DK (1) DK3792260T3 (https=)
EC (1) ECSP20078586A (https=)
ES (1) ES2992256T3 (https=)
FI (1) FI3792260T3 (https=)
HR (1) HRP20241414T1 (https=)
HU (1) HUE068695T2 (https=)
IL (1) IL278517B2 (https=)
LT (1) LT3792260T (https=)
MA (1) MA52587B1 (https=)
MD (1) MD3792260T2 (https=)
MX (1) MX2020011855A (https=)
MY (1) MY202833A (https=)
PE (1) PE20211384A1 (https=)
PH (1) PH12020551873A1 (https=)
PL (1) PL3792260T3 (https=)
PT (1) PT3792260T (https=)
RS (1) RS65996B1 (https=)
SA (1) SA520420487B1 (https=)
SG (1) SG11202011003TA (https=)
SI (1) SI3792260T1 (https=)
SM (1) SMT202400407T1 (https=)
TW (1) TWI868068B (https=)
UA (1) UA126774C2 (https=)
WO (1) WO2019216294A1 (https=)
ZA (1) ZA202007164B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992256T3 (es) 2018-05-08 2024-12-11 Nippon Shinyaku Co Ltd Compuestos de azabencimidazol y producto farmacéutico
BR112022008571A2 (pt) 2019-11-13 2022-08-09 Nippon Shinyaku Co Ltd Composto de azabenzimidazol e medicamento
WO2021095805A1 (ja) * 2019-11-13 2021-05-20 日本新薬株式会社 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤
CN118045050B (zh) * 2023-11-16 2025-06-10 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种头颈部放疗患者适用的缓解口腔干燥的组合物及其制备方法
WO2025153078A1 (zh) * 2024-01-17 2025-07-24 盛睿泽华医药科技(苏州)有限公司 可溶性环氧水解酶抑制剂及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571819A (en) 1994-11-22 1996-11-05 Sabb; Annmarie L. Imidazopyridines as muscarinic agents
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723142A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
EP1734820A4 (en) 2004-04-16 2008-01-23 Neurogen Corp Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
ES2274712B1 (es) * 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
PT2054405E (pt) 2006-07-11 2013-12-24 Dae Woong Pharma Novos derivados de biaril benzoimidazol e composição farmacêutica que compreende os mesmos
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
MX2010007587A (es) 2008-01-24 2010-08-04 Ucb Pharma Sa Compuestos que comprenden un grupo ciclobutoxi.
WO2010130392A1 (de) 2009-05-11 2010-11-18 Ratiopharm Gmbh Desfesoterodin in form eines weinsäuresalzes
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
JP5667934B2 (ja) * 2010-06-28 2015-02-12 大日本住友製薬株式会社 新規2環性複素環化合物からなる医薬
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CA2821834A1 (en) * 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP2013545779A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン
JP6038150B2 (ja) 2011-08-24 2016-12-07 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Nedd8活性化酵素阻害剤
JP2013237634A (ja) 2012-05-14 2013-11-28 Dainippon Sumitomo Pharma Co Ltd 縮環イミダゾロン誘導体
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
TWI647227B (zh) 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 2-醯胺噻唑衍生物或其鹽
EA031866B1 (ru) 2014-06-06 2019-03-29 Астеллас Фарма Инк. Производное 2-ациламинотиазола или его соль
BR112017003901A2 (pt) 2014-08-26 2017-12-12 Astellas Pharma Inc derivado de 2-aminotiazola ou sal do mesmo
JP6680297B2 (ja) 2015-04-28 2020-04-15 アステラス製薬株式会社 経口投与用医薬組成物
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
CN115504986B (zh) 2017-03-03 2024-05-14 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用
CA3085745A1 (en) 2017-12-21 2019-06-27 Kyorin Pharmaceutical Co., Ltd. An agent for treating nocturnal pollakiuria
WO2019189766A1 (ja) 2018-03-30 2019-10-03 持田製薬株式会社 新規ビアリールアミド誘導体
ES2992256T3 (es) 2018-05-08 2024-12-11 Nippon Shinyaku Co Ltd Compuestos de azabencimidazol y producto farmacéutico
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
WO2021095805A1 (ja) 2019-11-13 2021-05-20 日本新薬株式会社 機能性消化管障害及び口腔乾燥症の治療剤及び予防剤
BR112022008571A2 (pt) 2019-11-13 2022-08-09 Nippon Shinyaku Co Ltd Composto de azabenzimidazol e medicamento

Also Published As

Publication number Publication date
UA126774C2 (uk) 2023-02-01
WO2019216294A1 (ja) 2019-11-14
TW202016108A (zh) 2020-05-01
KR20210006437A (ko) 2021-01-18
TWI868068B (zh) 2025-01-01
MA52587B1 (fr) 2024-10-31
US12319683B2 (en) 2025-06-03
IL278517B2 (en) 2024-09-01
IL278517B1 (en) 2024-05-01
EP3792260B1 (en) 2024-09-11
CL2020002868A1 (es) 2021-04-16
CA3099655A1 (en) 2019-11-14
MY202833A (en) 2024-05-24
PL3792260T3 (pl) 2024-12-02
SI3792260T1 (sl) 2024-11-29
PT3792260T (pt) 2024-10-02
MA52587A (fr) 2021-03-17
AU2019265134B2 (en) 2024-02-29
SG11202011003TA (en) 2020-12-30
PH12020551873A1 (en) 2021-05-31
ES2992256T3 (es) 2024-12-11
ECSP20078586A (es) 2021-01-29
MX2020011855A (es) 2021-01-20
CN112368282A (zh) 2021-02-12
LT3792260T (lt) 2024-10-25
US20210371412A1 (en) 2021-12-02
BR112020022662A2 (pt) 2021-02-09
CN112368282B (zh) 2023-10-13
EP3792260A1 (en) 2021-03-17
HRP20241414T1 (hr) 2024-12-20
AU2019265134A1 (en) 2020-12-17
KR102819951B1 (ko) 2025-06-13
IL278517A (en) 2020-12-31
FI3792260T3 (fi) 2024-10-01
EP3792260A4 (en) 2022-02-09
CO2020013848A2 (es) 2021-01-29
RS65996B1 (sr) 2024-10-31
MD3792260T2 (ro) 2024-12-31
JP7235047B2 (ja) 2023-03-08
HUE068695T2 (hu) 2025-01-28
SA520420487B1 (ar) 2024-03-17
ZA202007164B (en) 2024-06-26
PE20211384A1 (es) 2021-07-27
JPWO2019216294A1 (ja) 2021-05-13
SMT202400407T1 (it) 2024-11-15

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
DK3565550T3 (da) Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
EP3645118C0 (en) SIMULATION-BASED DRUG TREATMENT PLANNING
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
DK3703785T3 (da) Lægemiddelindgivelsesanordning
UY4595S (es) Dispositivo portátil de administración de fármacos
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3493862T3 (da) Lægemiddelindgivelsesanordning
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
EP3689892A4 (en) RADIOACTIVE MEDICINAL PRODUCT
DK3603620T3 (da) Liposomsammensætning og farmaceutisk sammensætning
DK3514153T3 (da) Pyrimidinforbindelse og farmaceutisk anvendelse deraf
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
DK3792260T3 (da) Azabenzimidazolforbindelser og lægemiddel
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
DK3263565T3 (da) Cyklisk aminderivat og farmaceutisk anvendelse deraf
EP3735463A4 (en) Cytotoxicity-inducing therapeutic agent
DK3558438T3 (da) Lægemiddelindgivelsesanordning
DK3204085T3 (da) Hus og lægemiddeladministrationsanordning hermed
IL283900A (en) Pharmaceutical combinations
DK3615502T3 (da) Terapeutiske forbindelser og fremgangsmåder
DK3560925T3 (da) Hidtil ukendt forbindelse og farmaceutisk acceptabelt salt deraf
EP4169571C0 (en) THERAPY DEVICE
DK3914321T3 (da) Lægemiddeladministrationsanordning
IL282157A (en) Compounds and therapeutic uses thereof